Novartis Antihypertensives Rasilez, Exforge Could Reach Market By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The oral renin inhibitor Rasilez is one of two recently submitted Novartis cardiovascular products that could clear FDA by year-end